Abstract
Despite the wide availability of analgesics for prescription in cancer pain, including both opioid and non-opioid medications, population studies have for many years demonstrated unadvisable pain management. International analyses indicate inadequate use of opioid and adjuvant drugs per capita. At the same time, patients complain about the accompanying pain, not treated effectively, especially in the course of cancer. One of the many causes of cancer pain that is difficult to treat is the co-occurrence of neuropathic pain. The article presents contemporary views on the treatment of neuropathic pain associated with cancer, including the site of application of gabapentinoids in the treatment scheme.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
